PCM
ADPT icon

Prelude Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Prelude Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20,000
Closed -$805K – 1621
2021
Q1 		$805K Buy
+20,000
New +$1.08M 0.02% 688

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prelude Capital Management's ADPT Position: Q1 2026 in Review

Prelude Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q1 2026, closing a stake of 25,998 shares — an estimated $422K sold.

Prelude Capital Management first reported a position in ADPT in Q3 2019 and held it in 15 quarters. The position peaked at $2.02M in Q1 2022. 296 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • Prelude Capital Management reported no remaining Adaptive Biotechnologies position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 25,998 Adaptive Biotechnologies shares in Q1 2026, an estimated $422K.
  • Prelude Capital Management first reported a position in Adaptive Biotechnologies in Q3 2019 and held it in 15 quarters.
  • Prelude Capital Management's Adaptive Biotechnologies position peaked at $2.02M in Q1 2022.
  • 296 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.